G-CON selects Pall’s continuous bioprocessing and viral vector tech
According to the agreement, G-CON’s autonomous, mobile facilities, or ‘PODs’, can now be customised with Pall Biotech bioprocessing equipment.
G-CON launched its prefabricated business in October last year, in collaboration with Integrated Project Services (IPS).
This latest collaboration with Pall delivers “a complete, reproducible, scalable facility solution that is easy to place or relocate, as well as clean, sanitise and even repurpose,” said Pall Biotech vice president and general manager, Mario Philips, in an emailed statement.
“This solution addresses customer demand for higher efficiencies while enjoying more flexibility through scale-out and localisation of manufacturing,” he added.
According to G-CON, the predesigned PODs, which are integrated with process piping, as well as heating and air conditioning systems, are inherently flexible – the cleanrooms can support multiple products and be repurposed after use.
G-CON and Pall’s offering will compete with GE Healthcare Life Sciences’ KUBio modular bioprocessing facility, which as of April this year supports the manufacture of viral vector vaccines.
